We are excited to announce that our Principal, Ms. Pauli Wong, has been appointed as the Honorary IP Advisor by the Hong Kong Medical & Healthcare Device Industries Association (HKMHDIA) for the term 2025-2026. She will provide advice and guidance to support HKMHDIA’s mission in advocating for streamlined regulatory policies to position Hong Kong as a leader in medical technologies. 

Pauli has served many HKMHDIA members in the life sciences and medical devices sectors as their patent attorney over the past few years. She is eager to provide strategic guidance for the association, leveraging her deep understanding of intellectual property to help HKMHDIA members safeguard their innovations and enhance their competitive edge. 

We are confident that Pauli's expertise and dedication will greatly benefit HKMHDIA and its members, driving innovation and success in the life sciences and medical devices sector of Hong Kong. 

我们的过去活动

Recommended Insights

China’s Newest Examination Guidelines: Post-Filing Supplemental Data for Compounds (Part I)

2021年4月28日
Post-filing data in China has been a constant issue for many patent practitioners around the world. Examiners seem to require it often, and yet the rules regarding when it is acceptable have seemed much stricter than other jurisdictions worldwide. In fact, we tried to summarize the latest state of the law in an earlier blog […]

The Secret Prior Art Trap: A Case Study on Conflicting Applications in China

2025年11月13日
In patent prosecution, the concept of a "conflicting application" or “secret prior art” plays a critical role in determining the patentability of an invention. This article explores the framework for assessing conflicting applications under Chinese patent law, with a comparative perspective on the approaches adopted in the United States. Case Background: The Image Encoding Dispute […]

Introducing the New USPTO Cancer Moonshot Expedited Examination Pilot Program

2023年1月10日
Starting from February 1, 2023, the USPTO will begin the new Cancer Moonshot Expedited Examination Pilot Program that advances out-of-turn applications that are directed to oncology or smoking cessation. This new program will replace the Cancer Immunotherapy Pilot Program that has been in place since 2016, and covers more technologies than only cancer immunotherapies. Applications […]

China Patent Office (CNIPA) Releases More Details About Patent Term Adjustment (PTA) in the Draft Examination Guidelines

2021年10月19日
The new 4th Amendment of the Chinese Patent Law came into effect on June 1, 2021. Right before that date, the Chinese Patent Office (“CNIPA”) released some “Interim Measures” to give us a taste of what was to come, though they have yet to released the actual Implementation Rules. Two months later, CNIPA finally released […]
Top crossarrow-right